Back to Search
Start Over
Correction: Activation of RAS/MAPK pathway confers MCL-1 mediated acquired resistance to BCL-2 inhibitor venetoclax in acute myeloid leukemia.
- Source :
-
Signal transduction and targeted therapy [Signal Transduct Target Ther] 2022 Apr 01; Vol. 7 (1), pp. 110. Date of Electronic Publication: 2022 Apr 01. - Publication Year :
- 2022
Details
- Language :
- English
- ISSN :
- 2059-3635
- Volume :
- 7
- Issue :
- 1
- Database :
- MEDLINE
- Journal :
- Signal transduction and targeted therapy
- Accession number :
- 35365596
- Full Text :
- https://doi.org/10.1038/s41392-022-00958-4